3/26/2014

A gene expression profiling test can be used to evaluate the risk that primary cutaneous melanomas will metastasize after a negative sentinel lymph node biopsy. Researchers analyzed data involving 217 patients. "This gives clinicians a better way of identifying high-risk patients," said dermatologist Pedram Gerami.

Related Summaries